Difference between revisions of "Deferoxamine"
(Updated links and information for pharmacology/side effects)
|Line 59:||Line 59:|
Latest revision as of 23:52, 20 September 2019
- Type: Antidote
- Dosage Forms:
- Routes of Administration: IV, IM
- Common Trade Names: Desferal
- 1000mg IV; start at 5mg/kg/hr, increase up to 15mg/kg/hr as tolerated for up to 24hrs
- Subsequent doses are 500mg increments guided by clinical status of patient / urine color
- Recommended amount during first 24hr is 360mg/kg not to exceed 6g.
- 15 mg/kg/h IV
- Prolonged use >24-48 hours may increase risk of ARDS
- 100mg deferoxamine chelates 9mg free iron
- Pregnancy Rating:
- Lactation risk:
- Renal Dosing
- Adult: Contraindicated in severe impairment or anuria.
- Pediatric: Contraindicated in severe impairment or anuria
- Hepatic Dosing
- Adult: Not defined
- Pediatric: Not defined
- Systemic toxicity and iron level > 350 mcg/dL
- Metabolic acidosis
- Progressive symptoms
- Serum iron level >500 mcg/dL
- Allergy to class/drug
- Renal failure patients not on hemodialysis
- Hypotension (pre-existing hypotension is NOT a contraindication to therapy)
- Yersinia enterocolitica sepsis
- Can see "vin rose" colored urine from chelated iron extretion
- Cataracts with long term use
- Flushing, urticaria, fever, myalgia, nausea, vomiting
- Half-life: 6h
- Metabolism: Plasma
- Excretion: Urine, bile/feces
- Mechanism of Action:
- Chelates iron and creates a water-soluble compound ferrioxamine that is renally excreted and can be dialyzed.
- Mazzoleni G. et al. Yersinia enterocolitica infection with ileal perforation associated with iron overload and deferoxamine therapy. Dig Dis Sci 1991; 36:1154-1160.
- Cite error: Invalid
<ref>tag; no text was provided for refs named